Global Targeted Protein Degradation (TPD) Market Landscape Analysis 2022 by Technologies, Pipeline, Partnering and Financing – Focus on Proteasomal, Lysosomal & Autophagy Pathways – ResearchAndMarkets.com

Global Targeted Protein Degradation (TPD) Market Landscape Analysis 2022 by Technologies, Pipeline, Partnering and Financing – Focus on Proteasomal, Lysosomal & Autophagy Pathways – ResearchAndMarkets.com




Global Targeted Protein Degradation (TPD) Market Landscape Analysis 2022 by Technologies, Pipeline, Partnering and Financing – Focus on Proteasomal, Lysosomal & Autophagy Pathways – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: An Industry Landscape Analysis of Stakeholders, Technologies, Pipeline, Partnering and Financing” report has been added to ResearchAndMarkets.com’s offering.

This report describes and analyzes the field of Targeted Protein Degradation (TPD) from an industry perspective as of March 2022.

Targeted protein degradation is a strongly and rapidly emerging new therapeutic modality based on the promise to overcome limitations of traditional small molecule drug modalities, such as limited access to difficult-to-drug targets and development of drug resistance.

TPD technology is being adopted by most major pharmaceutical companies as it is regarded as a key technology platform. Pure-play TPD technology companies make progress by advancing their drug candidates into clinical studies. Many biotech companies are diversifying their platforms by adding TPD technology.

Investors welcome companies with TPD technologies as evidenced by the continuous flow of money to foster the development of TPD technology and TPD drug candidates. Since April of 2020, five pure-play TPD technology companies went public and successfully raised a total of US$ 2.14 bln.

The average market capitalization of five NASDAQ listed TPD technology companies was US$ 1.5 bln as of March 4, 2022. Series A-E financing rounds of 23 pure-play TPD technology companies brought in a total of US$ 1,778 mln of venture capital and equity investment. Partnering revenues are another important source of funding. As the TPD pipeline is maturing with favourable clinical outcomes, a recent licensing deal for a clinical phase II estrogen receptor PROTAC justified up-front payment and equity investment of US$ 1 bln.

This report describes and analyzes the industry landscape of targeted protein degradation by proteasomal-, lysosomal- and autophagy-targeted technologies. The report is based on information retrieved from 69 technology companies, 23 pharmaceutical companies and three academic institutions with publicly known industry ties.

Description of pharmaceutical companies generally is limited to activities with respect to TPD for publicly known in-house activities, for R&D collaboration and licensing and for acquisitions (Merck, Bayer, Amgen and Bristol Myers Squib).

The heterogeneous profiles of the 69 technology companies demands assignation to “clusters” of companies with similar characteristics to allow a systematic comparison of 33 pure-play TPD technology companies focused on proteasomal pathway or non-proteasomal pathway technologies; 26 technologically diversified companies with TPD technologies; and the remainder of 10 companies.

Specific profiles are provided for 31 TPD technologies, separately for proteasomal molecular glue/monovalent degrader; proteasomal heterobifunctional degraders, lysosomal & autophagy pathway degraders and the remainder.

Specific profiles are provided for 48 TPD drug candidates, separately for the same four TPD modalities as for TPD technologies.

All information in the three chapters of Company Profiles, Technology Profiles and Drug Candidate Profiles are fully referenced with 117 scientific references, in most cases with hyperlinks with immediate online access to the source of information (abstracts, Poster, Presentations).

Non-scientific references, such as press releases, annual reports or company presentations, are disclosed within the text with an embedded hyperlink leading to the source of information. Details about R&D strategy, collaboration and licensing agreements, acquisitions, financing rounds and sources are described in the company profiles.

The report provides essential information about and analysis of:

  • Pure-play TPD technology companies (molecular glues, heterobifunctional degraders, lysosomal and autophagic pathway degraders)
  • Diversified technology companies with a TPD platform
  • Major pharma companies with a stake in TPD (in-house, partnering, licensing, acquisition)
  • Proteasomal protein degrader technologies (heterobifunctional, molecular glue, monovalent degrader)
  • Rational approaches for monofunctional molecular glue discovery at industry scale
  • Lysosomal and autophagy pathway degrader technologies (LYTACs, AUTOTACs, ATTECs etc)
  • Clinical and preclinical experience with molecular glues and PROTACs
  • Profiles of TPD Drug Candidates
  • TPD Pipeline Analysis
  • Preferred Targets of TPDs
  • Preferred E3 ligases and their binders
  • Technologies for discovery of binders to proteins-of-interest and E3 ligases
  • Venture capital financing of TPD technology companies
  • Financing by IPO and follow-on public offerings
  • Revenues from TPD discovery and licensing deals

Key Topics Covered:

1 Executive Summary

2 Introduction, Overview & Methodology

3 Analysis of TPD Stakeholders

3.1 Targeted Protein Degradation (TPD) Technology Companies

3.1.1 Overview

3.1.2 Pure-Play TPD Companies Focused on Molecular Glue & Monovalent Proteasomal Degraders

3.1.3 Pure-Play TPD Companies Focused on Heterobifunctional Proteasomal Degraders

3.1.4 Pure-Play TPD Companies Focused on Molecular Glue & Heterobifunctional Proteasomal Degraders

3.1.5 Pure-Play TPD Companies Focused on Lysosomal & Autophagic (Non-Proteasomal) Degradation Technologies

3.1.6 Diversified Technology Companies with One Focus on Heterobifunctional Proteasomal Degraders

3.1.7 Diversified Technology Companies with Various TPD Technology Profiles

3.1.8 Remainder of Technology Companies with Various TPD Technology Profiles

3.2 Pharmaceutical Companies with TPD Interests

3.2.1 Overview of Major Pharma Companies as Stakeholders in TPD

3.2.2 Profile of Major Pharma’s Interest in Targeted Protein Degradation (TPD) R&D

3.2.3 Scope of Major Pharma’s Partnering Activities in Targeted Protein Degradation (TPD)

4 Analysis of TPD Technologies

4.1 Analysis of Molecular Glue & Monovalent Proteasomal TPD Technologies

4.2 Analysis of Heterobifunctional Proteasomal TPD Technologies

4.3 Analysis of Lysosomal & Autophagy Pathway TPD Technologies

4.4 Remainder of TPD Technologies

5 Analysis of TPD Pipeline, Targets and Product Candidates

5.1 Molecular Glue & Monovalent Proteasomal Targeted Protein Degraders

5.1.1 Clinical & Non-Clinical Development Pipeline of Molecular Glue Degraders: Targets and Experience

5.1.2 Preclinical R&D Pipeline & Targets of Molecular Glue & Monovalent Protein Degraders

5.2 Heterobifunctional Proteasomal Targeted Protein Degraders

5.2.1 Clinical & Non-Clinical Development Pipeline of Heterobifunctional Degraders

5.2.2 Preclinical R&D Pipeline of Heterobifunctional Degraders

5.2.3 Protein-of-Interest Targets and E3 Ligases Addressed by Heterobifunctional Proteasomal Degraders

5.2.4 E3 Ligases and Binders

5.3 Lysosomal & Autophagy Pathway Protein Degraders

5.4 Remainder of Targeted Protein Degraders

6 Business, Financing & Partnering

7 Profiles of Stakeholders in Targeted Protein Degradation (TPD)

7.1 Pure-Play TPD Companies Focused on Molecular Glue & Monovalent Proteasomal Degraders

7.2 Pure-Play TPD Companies Focused on Heterobifunctional Proteasomal Degraders

7.3 Pure-Play TPD Companies Focused on Molecular Glue & Heterobifunctional Proteasomal Degraders

7.4 Pure-Play TPD Companies Focused on Lysosomal & Autophagic (Non-Proteasomal) Degraders

7.5 Diversified Technology Companies with One Focus on Heterobifunctional Proteasomal Degraders

7.6 Diversified Technology Companies with Various TPD Technology Profiles

7.7 Remainder of Technology Companies with Various TPD Technology Profiles

7.8 Pharmaceutical Companies with Stakes in Targeted Protein Degradation

7.9 Academia with TPD Industry Partnerships

8 Profiles of Targeted Protein Degradation (TPD) Technologies

8.1 Profiles of Molecular Glue & Monovalent TPD Technologies

8.2 Profiles of Heterobifunctional Proteasomal TPD Technologies

8.3 Profiles of Lysosomal & Autophagy Pathway TPD Technologies

8.4 Other TPD-Related Technologies

9 Profiles of TPD Product Candidates

9.1 Molecular Glue & Monovalent Protein Degraders

9.2 Heterobifunctional Proteasomal Targeted Protein Degraders

9.3 Lysosomal & Autophagy Pathway Protein Degraders

9.4 Remainder of Targeted Protein Degraders – Not Defined

10 References

ADDENDUM: Competitor Analysis

Add 1 Molecular Glue & Monovalent Small Molecule Proteasomal Targeted Protein Degradation

Add 2 Heterobifunctional Proteasomal Targeted Protein Degradation

Add 3 Lysosomal & Autophagy Pathway Targeted Protein Degradation

Add 4 Remainder of Targeted Protein Degradation

Companies Mentioned

  • AbbVie
  • Accelero Biostructures
  • Amgen
  • Amphista Therapeutics
  • AnHorn Medicines
  • Arvinas
  • Ascentage Pharma
  • Aurigene Discovery
  • AUTOTAC Bio
  • Bayer
  • BeiGene
  • Biogen
  • Biohaven Pharmaceutical Holding Company
  • BioTheryX
  • Blueprint Medicines
  • Boehringer Ingelheim
  • Bristol Myers Squibb
  • C4 Therapeutics
  • Calico
  • Calporta Therapeutics
  • Captor Therapeutics
  • Caraway Therapeutics
  • Casma Therapeutics
  • Celeris Therapeutics
  • Centessa Pharmaceuticals
  • Coho Therapeutics
  • ComInnex
  • Cullgen
  • Cullinan Oncology
  • Dalriada
  • Deargen
  • Debiopharm
  • Degron Therapeutics
  • Dialectic Therapeutics
  • Dunad Therapeutics
  • Eli Lilly
  • f5 Therapeutics
  • FIMECS
  • Frontier Medicines
  • Gilead Sciences
  • GlaxoSmithKline
  • Haisco Pharmaceutical Group
  • Hinova Pharmaceuticals
  • HitGen
  • Hoth Therapeutics
  • Insilico Medicines
  • Isoprene Pharmaceuticals
  • Janpix / Centessa Pharmaceuticals
  • Janssen Pharmaceutical Group of Companies
  • JW Pharmaceutical
  • Kangpu Biopharmaceuticals
  • Kymera Therapeutics
  • Lycia Therapeutics
  • Macroceutics (Hotspot Therapeutics)
  • Merck & Co
  • Merck KGaA
  • Monte Rosa Therapeutics
  • NeoImmuneTech
  • Novartis
  • Nurix Therapeutics
  • Origami Therapeutics
  • Orionis Biosciences
  • Orum Therapeutics
  • Pfizer
  • Pin Therapeutics
  • Plexion
  • Polymed Biopharmaceuticals
  • PolyProx Therapeutics
  • Prazer Therapeutics
  • Progenra
  • Proteovant Therapeutics
  • Proxygen
  • Ranok Therapeutics
  • Ribon Therapeutics
  • Roche
  • Ryvu Therapeutics
  • Sanofi
  • Seed Therapeutics
  • SK Holdings
  • Sosei Heptares
  • Trilo Therapeutics
  • Ubix Therapeutics
  • University of Dundee (Centre for Targeted Protein Degradation)
  • Uppthera
  • VectorY Therapeutics
  • Venquis Therapeutics
  • Vertex Pharmaceuticals
  • Vipergen
  • Vividion Therapeutics
  • Voronoi
  • XPose Therapeutics

For more information about this report visit https://www.researchandmarkets.com/r/2pz2id

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T. Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900